Raymond James & Associates Has $194.50 Million Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Raymond James & Associates grew its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 2.5% in the third quarter, Holdings Channel reports. The institutional investor owned 820,771 shares of the medical research company’s stock after acquiring an additional 20,397 shares during the period. Raymond James & Associates’ holdings in IQVIA were worth $194,498,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in IQV. Versant Capital Management Inc boosted its holdings in IQVIA by 733.3% during the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after purchasing an additional 110 shares during the last quarter. Opal Wealth Advisors LLC purchased a new position in IQVIA during the second quarter worth about $27,000. Park Place Capital Corp purchased a new position in IQVIA during the third quarter worth about $28,000. Itau Unibanco Holding S.A. purchased a new position in IQVIA during the second quarter worth about $29,000. Finally, Riverview Trust Co purchased a new position in IQVIA during the first quarter worth about $32,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Trading Up 1.2 %

Shares of NYSE IQV opened at $236.69 on Friday. IQVIA Holdings Inc. has a 1 year low of $167.42 and a 1 year high of $261.73. The stock has a market cap of $43.15 billion, a P/E ratio of 30.74, a price-to-earnings-growth ratio of 2.22 and a beta of 1.49. The firm has a 50-day moving average of $239.08 and a 200 day moving average of $231.16. The company has a debt-to-equity ratio of 1.80, a current ratio of 0.85 and a quick ratio of 0.85.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.57 by $0.07. The company had revenue of $3.81 billion during the quarter, compared to analysts’ expectations of $3.79 billion. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. IQVIA’s revenue was up 2.3% on a year-over-year basis. During the same period last year, the company posted $2.22 EPS. As a group, sell-side analysts expect that IQVIA Holdings Inc. will post 10.25 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. StockNews.com upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a report on Monday, October 14th. Robert W. Baird lifted their price objective on shares of IQVIA from $251.00 to $256.00 and gave the stock a “neutral” rating in a research report on Friday, September 20th. Evercore ISI lowered their price objective on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. JPMorgan Chase & Co. lifted their price objective on shares of IQVIA from $260.00 to $288.00 and gave the stock an “overweight” rating in a research report on Monday, August 5th. Finally, Truist Financial lowered their price target on shares of IQVIA from $300.00 to $286.00 and set a “buy” rating on the stock in a research report on Monday, October 14th. Four investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $267.87.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the sale, the insider now directly owns 19,536 shares in the company, valued at $4,812,302.88. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 1.60% of the stock is owned by company insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.